Amicus Therapeutics Inc. (NASDAQ:FOLD)‘s stock had its “outperform” rating reiterated by stock analysts at Cowen and Company in a research report issued on Tuesday. They presently have a $15.00 price objective on the biopharmaceutical company’s stock. Cowen and Company’s price target indicates a potential upside of 68.54% from the company’s previous close.
A number of other research firms have also weighed in on FOLD. Zacks Investment Research lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, August 2nd. Chardan Capital set a $15.00 target price on shares of Amicus Therapeutics and gave the stock a “buy” rating in a research note on Thursday, August 11th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $12.19.
Shares of Amicus Therapeutics (NASDAQ:FOLD) opened at 8.90 on Tuesday. Amicus Therapeutics has a 52 week low of $4.98 and a 52 week high of $11.58. The firm’s 50-day moving average is $7.81 and its 200 day moving average is $6.95. The firm’s market capitalization is $1.27 billion.
Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.34) by $0.01. The business had revenue of $2.10 million for the quarter, compared to analyst estimates of $1.71 million. On average, equities analysts forecast that Amicus Therapeutics will post ($1.38) earnings per share for the current year.
In other Amicus Therapeutics news, SVP Daphne Quimi sold 8,546 shares of the stock in a transaction that occurred on Wednesday, November 9th. The shares were sold at an average price of $8.00, for a total value of $68,368.00. Following the transaction, the senior vice president now directly owns 24,189 shares in the company, valued at $193,512. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Hung Do sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 6th. The stock was sold at an average price of $7.00, for a total transaction of $175,000.00. Following the transaction, the insider now owns 583,453 shares in the company, valued at $4,084,171. The disclosure for this sale can be found here. 3.40% of the stock is currently owned by company insiders.
Institutional investors have recently made changes to their positions in the company. M&T Bank Corp acquired a new position in shares of Amicus Therapeutics during the first quarter worth about $157,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of Amicus Therapeutics during the second quarter worth about $108,000. SG Americas Securities LLC acquired a new position in shares of Amicus Therapeutics during the third quarter worth about $151,000. Principal Financial Group Inc. raised its position in shares of Amicus Therapeutics by 10.5% in the second quarter. Principal Financial Group Inc. now owns 22,411 shares of the biopharmaceutical company’s stock worth $122,000 after buying an additional 2,122 shares during the period. Finally, BlackRock Inc. raised its position in shares of Amicus Therapeutics by 224.8% in the second quarter. BlackRock Inc. now owns 26,443 shares of the biopharmaceutical company’s stock worth $144,000 after buying an additional 18,301 shares during the period.
Amicus Therapeutics Company Profile